-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $20.00 at SVB Leerink
Pharvaris (NASDAQ:PHVS) Price Target Lowered to $20.00 at SVB Leerink
Pharvaris (NASDAQ:PHVS – Get Rating) had its target price reduced by SVB Leerink from $25.00 to $20.00 in a report published on Wednesday, The Fly reports. SVB Leerink currently has an outperform rating on the stock.
Several other research analysts have also commented on PHVS. JMP Securities dropped their price target on shares of Pharvaris from $34.00 to $18.00 and set a mkt outperform rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Pharvaris from an overweight rating to an equal weight rating and dropped their price target for the stock from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Pharvaris from $48.00 to $22.00 and set an outperform rating on the stock in a research note on Tuesday, August 23rd. Finally, Bank of America lowered shares of Pharvaris from a neutral rating to an underperform rating and dropped their price target for the stock from $26.00 to $13.00 in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Pharvaris has a consensus rating of Hold and an average price target of $16.60.
Get Pharvaris alerts:Pharvaris Trading Up 0.8 %
Shares of NASDAQ PHVS opened at $9.14 on Wednesday. The firm has a market capitalization of $291.06 million, a PE ratio of -3.52 and a beta of -0.19. The business has a 50-day moving average price of $16.74 and a two-hundred day moving average price of $17.99. Pharvaris has a one year low of $8.55 and a one year high of $27.50.
Pharvaris (NASDAQ:PHVS – Get Rating) last issued its quarterly earnings data on Monday, September 12th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.19. Research analysts anticipate that Pharvaris will post -2.18 EPS for the current year.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter. DAFNA Capital Management LLC grew its position in Pharvaris by 4.7% in the 4th quarter. DAFNA Capital Management LLC now owns 36,720 shares of the company's stock worth $528,000 after purchasing an additional 1,646 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Eventide Asset Management LLC grew its position in Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Finally, Novo Holdings A S grew its position in Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company's stock worth $7,430,000 after purchasing an additional 97,378 shares during the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
Pharvaris Company Profile
(Get Rating)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Read More
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
Pharvaris (NASDAQ:PHVS – Get Rating) had its target price reduced by SVB Leerink from $25.00 to $20.00 in a report published on Wednesday, The Fly reports. SVB Leerink currently has an outperform rating on the stock.
据The Fly报道,在周三发布的一份报告中,SVB Leerink将Pharvaris(纳斯达克:PHVS-GET Rating)的目标价从25.00美元下调至20.00美元。SVB Leerink目前对该股的评级为跑赢大盘。
Several other research analysts have also commented on PHVS. JMP Securities dropped their price target on shares of Pharvaris from $34.00 to $18.00 and set a mkt outperform rating on the stock in a research note on Tuesday. Morgan Stanley lowered shares of Pharvaris from an overweight rating to an equal weight rating and dropped their price target for the stock from $40.00 to $10.00 in a research note on Tuesday, August 23rd. Oppenheimer dropped their price target on shares of Pharvaris from $48.00 to $22.00 and set an outperform rating on the stock in a research note on Tuesday, August 23rd. Finally, Bank of America lowered shares of Pharvaris from a neutral rating to an underperform rating and dropped their price target for the stock from $26.00 to $13.00 in a research note on Monday, August 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, Pharvaris has a consensus rating of Hold and an average price target of $16.60.
其他几位研究分析师也对PHV发表了评论。JMP Securities周二在一份研究报告中将Pharvaris的目标价从34.00美元下调至18.00美元,并对该股设定了Mkt的表现优于大盘的评级。在8月23日星期二的一份研究报告中,摩根士丹利将Pharvaris的股票评级从增持下调至持平评级,并将该股的目标价从40美元下调至10美元。奥本海默在8月23日(星期二)的一份研究报告中将Pharvaris的股票目标价从48.00美元下调至22.00美元,并对该股设定了强于大盘的评级。最后,在8月22日星期一的一份研究报告中,美国银行将Pharvaris的股票评级从中性下调至表现不佳,并将其股票目标价从26.00美元下调至13.00美元。一名分析师对该股的评级为卖出,一名分析师给出了持有评级,两名分析师给出了该公司的买入评级。根据MarketBeat的数据,Pharvaris的共识评级为持有,平均目标价为16.60美元。
Pharvaris Trading Up 0.8 %
Pharvaris股价上涨0.8%
Shares of NASDAQ PHVS opened at $9.14 on Wednesday. The firm has a market capitalization of $291.06 million, a PE ratio of -3.52 and a beta of -0.19. The business has a 50-day moving average price of $16.74 and a two-hundred day moving average price of $17.99. Pharvaris has a one year low of $8.55 and a one year high of $27.50.
周三,纳斯达克PHV的股价开盘报9.14美元。该公司市值为2.9106亿美元,市盈率为-3.52,贝塔系数为-0.19。该业务的50日移动均线价格为16.74美元,200日移动均线价格为17.99美元。Pharvaris的一年低点为8.55美元,一年高位为27.50美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Pharvaris by 1,054.4% in the 1st quarter. Bank of America Corp DE now owns 5,772 shares of the company's stock worth $105,000 after purchasing an additional 5,272 shares during the last quarter. DAFNA Capital Management LLC grew its position in Pharvaris by 4.7% in the 4th quarter. DAFNA Capital Management LLC now owns 36,720 shares of the company's stock worth $528,000 after purchasing an additional 1,646 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Pharvaris by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company's stock worth $1,259,000 after purchasing an additional 1,115 shares during the last quarter. Eventide Asset Management LLC grew its position in Pharvaris by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company's stock worth $5,659,000 after purchasing an additional 57,694 shares during the last quarter. Finally, Novo Holdings A S grew its position in Pharvaris by 23.2% in the 4th quarter. Novo Holdings A S now owns 516,321 shares of the company's stock worth $7,430,000 after purchasing an additional 97,378 shares during the last quarter. 70.21% of the stock is currently owned by institutional investors and hedge funds.
一些对冲基金和其他机构投资者最近买卖了该公司的股票。美国银行DE在第一季度将其在Pharvaris的头寸增加了1054.4%。美国银行DE目前持有5,772股该公司股票,价值105,000美元,此前该公司在上一季度又购买了5,272股。Dafna Capital Management LLC在第四季度将其在Pharvaris的头寸增加了4.7%。达夫纳资本管理有限责任公司现在拥有36,720股该公司的股票,价值528,000美元,在上个季度又购买了1,646股。高盛股份有限公司在第二季度增加了其在Pharvaris的头寸2.0%。高盛股份有限公司在上个季度增持了1,115股后,现在持有56,951股该公司股票,价值1,259,000美元。第一季度,Evende Asset Management LLC在Pharvaris的头寸增加了23.6%。Evende Asset Management LLC在上个季度额外购买了57,694股后,现在拥有302,619股该公司股票,价值5,659,000美元。最后,Novo Holdings A S在第四季度增加了其在Pharvaris的头寸23.2%。Novo Holdings A S现在持有该公司516,321股股票,价值7,43万美元,上个季度又购买了97,378股。70.21%的股票目前由机构投资者和对冲基金持有。
Pharvaris Company Profile
Pharvaris公司简介
(Get Rating)
(获取评级)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
Pharvaris N.V.是一家临床阶段的生物制药公司,专注于罕见疾病疗法的开发和商业化。该公司开发了PHA121,这是一种小分子缓激肽B2受体拮抗剂,目前处于第二阶段临床试验,用于治疗遗传性血管性水肿(HAE)。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Pharvaris (PHVS)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- 免费获取StockNews.com关于Pharvaris(PHV)的研究报告
- 这家医疗设备制造商准备好继续反弹了吗?
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马?
- 具有有趣内幕活动的四只廉价股票
- 健康饮料制造商Celsius能否超越其Monster竞争对手?
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
接受Pharvaris Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Pharvaris和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧